Are We Underdosing Patients With Ewing Sarcoma?
A new study evaluated whether busulfan and melphalan improve EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction. (Source: CancerNetwork)
Source: CancerNetwork - October 25, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Time to Rethink Chemo Doses in High-Risk, Localized Ewing Sarcoma?
A new study evaluated whether busulfan and melphalan improve EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction. (Source: CancerNetwork)
Source: CancerNetwork - October 23, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Brave eight-year-old boy battles second bout of brain cancer since he was just two
Jaxon Dugger, eight, from Hollis, Oklahoma, was fist diagnosed with Ewing sarcoma when he was just two years old. Three months after being declared cancer-free, his tumor returned. (Source: the Mail online | Health)
Source: the Mail online | Health - September 12, 2018 Category: Consumer Health News Source Type: news
Children's bone cancers could remain hidden for years before diagnosis
(Wellcome Trust Sanger Institute) Scientists have discovered that some childhood bone cancers start growing years before they are diagnosed. Researchers at the Wellcome Sanger Institute, UK and Hospital for Sick Children (SickKids), Canada discovered large-scale genetic rearrangements in Ewing Sarcomas and other children's cancers, and showed these can take years to form. The study in Science will help unravel causes of childhood cancers and could help find ways to diagnose and treat these cancers earlier in the future. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 30, 2018 Category: Cancer & Oncology Source Type: news
Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors
Sarcomas are cancers of the bone and soft tissue often defined by gene fusions. Ewing sarcoma involves fusions between EWSR1, a gene encoding an RNA binding protein, and E26 transformation-specific (ETS) transcription factors. We explored how and when EWSR1-ETS fusions arise by studying the whole genomes of Ewing sarcomas. In 52 of 124 (42%) of tumors, the fusion gene arises by a sudden burst of complex, loop-like rearrangements, a process called chromoplexy, rather than by simple reciprocal translocations. These loops always contained the disease-defining fusion at the center, but they disrupted multiple additional genes....
Source: ScienceNOW - August 30, 2018 Category: Science Authors: Anderson, N. D., de Borja, R., Young, M. D., Fuligni, F., Rosic, A., Roberts, N. D., Hajjar, S., Layeghifard, M., Novokmet, A., Kowalski, P. E., Anaka, M., Davidson, S., Zarrei, M., Id Said, B., Schreiner, L. C., Marchand, R., Sitter, J., Gokgoz, N., Brun Tags: Genetics, Medicine, Diseases, Online Only r-articles Source Type: news
MGH team defines the mechanisms of action of key genetic abnormality in Ewing sarcoma
(Massachusetts General Hospital) A Massachusetts General Hospital research team has used epigenome editing tools to investigate how the genetic abnormality that drives Ewing sarcoma -- the second most common bone cancer in children and young adults -- unleashes tumor growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2018 Category: Cancer & Oncology Source Type: news
New connections: Ewings sarcomas driver is its Achilles heel
Several studies identify drug combinations that target or exploit the EWS-FLI1 fusion protein to kill Ewing’s sarcoma cells. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - April 24, 2018 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news
A potential new therapeutic target for Ewing sarcoma
(IDIBELL-Bellvitge Biomedical Research Institute) IDIBELL researchers correlate EphA2 membrane receptor with the metastatic capacity of tumors in Ewing sarcoma.Ewing sarcoma is the second most frequent bone cancer among children and adolescents, and it is characterized by its aggressiveness and tendency to metastasize.Researchers are currently working on nanoengineering a molecule capable of blocking EphA2 and deliver drugs in a targeted manner.Research was possible thanks to the backing of Alba P é rez Foundation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 5, 2018 Category: Cancer & Oncology Source Type: news
Greehey Institute team finds link between BRCA1 and Ewing sarcoma
(University of Texas Health Science Center at San Antonio) Scientists with the Greehey Children's Cancer Research Institute at UT Health San Antonio have discovered a surprising connection between a breast cancer protein, BRCA1, and a pediatric cancer called Ewing sarcoma. Their findings were made public March 7 online in the journal Nature. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 7, 2018 Category: Cancer & Oncology Source Type: news
Scientists tackle the aberrant epigenetic programming underlying childhood cancers
(Write Science Right) Researchers at UFRGS and the US NIH have targeted proteins that regulate chromatin in Ewing sarcoma cells, hindering malignant tumor growth. They induced chromatic relaxation by treating the cells with histone deacetylase inhibitors, reducing expression of the EWSR1-FLI-1 oncogene and other pluripotency/cell viability genes, while impairing sarcoma cell survival and growth. Decreased survival of stem-like cancer cells and re-expression of a neuronal differentiation marker were also observed. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2018 Category: International Medicine & Public Health Source Type: news
Unique research approach finds FDA-approved drug shuts down Ewing sarcoma cells in lab
(Georgetown University Medical Center) Based on a novel approach to drug discovery, researchers at Georgetown Lombardi Comprehensive Cancer Center say an agent approved to treat a type of leukemia might also help young people with a much rarer and aggressive form of cancer, Ewing sarcoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2018 Category: Cancer & Oncology Source Type: news
Cancer Researchers Hit Bullseye with New Drug Target for Ewing Sarcoma
The revelation brings a surge of hope to the field of pediatric oncology which has long been challenged to find new drugs against childhood cancers (Source: Disabled World)
Source: Disabled World - January 26, 2018 Category: Disability Tags: Cancer - Tumors Source Type: news
Cancer researchers hit a bullseye with new drug target for Ewing sarcoma
(Boston Children's Hospital) Kimberly Stegmaier of Dana-Farber/Boston Children's Cancer and Blood Disorders Center and collaborators have found that Ewing sarcoma cells die if an enzyme called CDK12 is knocked out genetically or chemically inhibited. What's more, when a CDK12 inhibitor is combined with another drug, called a PARP inhibitor, the two drugs double down to deliver a lethal punch to Ewing sarcoma cells. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 25, 2018 Category: Biology Source Type: news
PharmaMar presents positive results from a Phase II study of PM1183 in Ewing's sarcoma
(Pharmamar) PharmaMar (MSE:PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing ´ s sarcoma at the Connective Tissue Oncology Society ´ s (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news
Two classes of GGAA-microsatellites in a Ewing sarcoma context
(Nationwide Children's Hospital) In a study published in PLOS ONE, researchers describe two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. Ewing sarcoma is the second most common pediatric bone malignancy. It is initiated by chromosomal translocation t(11;22)(q24;q12), which creates the fusion protein and oncogenic driver EWS/FLI. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2017 Category: Cancer & Oncology Source Type: news
